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Abstract The trimeric protein AMP-activated protein
kinase (AMPK) is an important sensor of energetic status
and cellular stress, and mutations in genes encoding two of
the regulatory c subunits cause inherited disorders of either
cardiac or skeletal muscle. AMPKc2 mutations cause
hypertrophic cardiomyopathy with glycogen deposition
and conduction abnormalities; mutations in AMPKc3
result in increased skeletal muscle glycogen. In order to
gain further insight into the roles of the different c subunits
in muscle and into possible disease mechanisms, we
localised the c2 and c3 subunits, along with the more
abundant c1 subunit, by immunofluorescence in cardio-
myocytes and skeletal muscle fibres. The predominant
cardiac c2 variant, c2-3B, gave a striated pattern in
cardiomyocytes, aligning with the Z-disk but with punctate
staining similar to T-tubule (L-type Ca2? channel) and
sarcoplasmic reticulum (SERCA2) markers. In skeletal
muscle fibres AMPKc3 localises to the I band, presenting a
uniform staining that flanks the Z-disk, also coinciding
with the position of Ca2? influx in these muscles. The
localisation of c2-3B- and c3-containing AMPK suggests
that these trimers may have similar functions in the dif-
ferent muscles. AMPK containing c2-3B was detected in
oxidative skeletal muscles which had low expression of c3,
confirming that these two regulatory subunits may be co-
ordinately regulated in response to metabolic requirements.
Compartmentalisation of AMPK complexes is most likely
dependent on the regulatory c subunit and this differential
localisation may direct substrate selection and specify
particular functional roles.
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Introduction
AMPK regulates cellular energy homeostasis by monitor-
ing the energy status of the cell (Hardie 2007). It is a
hetero-trimeric complex (abc), a being the catalytic sub-
unit. In mammals, there are two or three isoforms of each
subunit (a1 and a2; b1 and b2; c1, c2 and c3), each
encoded by different genes (Hardie et al. 1998; Cheung
et al. 2000). Differences in the tissue distribution of iso-
forms (Stapleton et al. 1997; Thornton et al. 1998; Turnley
et al. 1999) and in muscle fibre type specific expression
patterns have been reported (Durante et al. 2002; Winder
et al. 2003; Mahlapuu et al. 2004). The regulatory c sub-
units bind adenine nucleotides in the highly conserved
nucleotide-binding domain consisting of four cystathio-
nine-b-synthase (CBS) motifs. AMPK is allosterically
activated when the AMP/ATP and ADP/ATP ratio
increases; complexes containing the a2 and c2 subunit
isoforms are stimulated to a greater extent by AMP than
those containing a1 and c1 (Salt et al. 1998; Cheung et al.
2000; Oakhill et al. 2011), and those containing c3 are least
sensitive to AMP (Scott et al. 2004). The c1 subunit is the
most abundant and shows wide tissue expression, as does
c2 whereas the c3 isoform is almost exclusively expressed
in skeletal muscle (Lang et al. 2000; Barnes et al. 2004;
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Mahlapuu et al. 2004; Yu et al. 2004). Transcription from
different promoters of the gene encoding AMPKc2
(PRKAG2) generates at least three transcripts in cardio-
myocytes (Fig. 1): one comprising the nucleotide binding
domain only (c2-short) and two longer transcripts (c2-long
and c2-3B) both consisting of the nucleotide binding
domain plus an N-terminal extension of different length
(Cheung et al. 2000; Lang et al. 2000; Pinter et al. 2012a).
The c2-3B subunit is the predominant c2 form in heart
along with c2-short, and its expression in other tissues is
low or negligible; c2-long is poorly expressed in the heart
(Cheung et al. 2000; Lang et al. 2000; Pinter et al. 2012a).
Mutations in PRKAG2 have been shown to cause car-
diac hypertrophy with associated glycogen deposition,
Wolff-Parkinson-White syndrome and conduction abnor-
malities (Blair et al. 2001; Gollob et al. 2001; Arad et al.
2002; Kim et al. 2009). All reported mutations are within
the nucleotide-binding domain, and functional studies have
suggested both that the basal level of activity is increased
(Hamilton et al. 2001) and that nucleotide binding is lower
or even abolished in the mutant protein resulting in
impairment of AMPK activation (Steinberg and Kemp
2009). Interestingly, there is a reported mutation (R225Q)
in c3 occurring naturally in pig (Milan et al. 2000) and in
human (R225W) (Costford et al. 2007); these mutations
cause increased glycogen deposition in skeletal muscle in
both cases, probably via increased glucose uptake rather
than decreased glycogen utilisation (Andersson 2003). The
amino acid affected by the c3 mutation occupies the same
position within the first CBS domain as the R302Q c2
mutation.
The precise subcellular localisation of AMPK com-
plexes within muscle cells is unclear. The b2 isoform, and
hence trimers containing this subunit, was localized in the
M-line in muscle fibres (Ponticos et al. 1998). In a different
study, it was demonstrated that a1/c1-containing AMPK is
found in the Z-disk, apparently mediated by interaction of
c1 with plectin (Gregor et al. 2006), suggesting that, at
least in this case, the regulatory subunit is responsible for
AMPK compartmentalisation. In support of this, our work
using human umbilical vein endothelial cells (HUVECs)
also suggests that the c subunit appears to determine
AMPK localisation (Pinter et al. 2012b). Furthermore,
selective activation of a2/b2/c3 AMPK complexes during
exercise has been reported in skeletal muscle and this was
suggested to be due to the subcellular localisation of this
AMPK complex, possibly directed by c3 (Birk and Wo-
jtaszewski 2006). Cell fractionation of mouse heart tissue
found that all AMPK c2 proteins were retained in the
cytoskeletal fraction (Pinter et al. 2012a), suggesting a
possible sarcomeric localisation. A yeast two-hybrid screen
of a human heart cDNA library identified cardiac troponin I
as an interactor with amino acids 1–273 of c2-long,
indicating that AMPK with c2 is associated with the thin
filaments (Oliveira et al. 2012).
As several different c subunit isoforms and variants can
and indeed are expressed in a cell (Cheung et al. 2000;
Lang et al. 2000; Pinter et al. 2012a), we hypothesize that
the different AMPK complexes have different functions,
and function depends on their subcellular localisation that
may be determined by the c subunit. We have already
demonstrated that AMPK complexes with distinct subunit
compositions are compartmentalised and assigned for dif-
ferent cellular functions (Pinter et al. 2012b). In this study
we provide further support for this notion by using
immunofluorescence technique and detecting differential
localisation of AMPK complexes with different c subunits
in mouse cardiomyocytes and in skeletal muscle fibres.
Methods
Animals and tissue collection
Ventricular cardiomyocytes were isolated from the heart
C57BL/6 mice as described previously (Sears et al. 2003;
Zhang et al. 2008); skeletal muscles (EDL, white quadri-
ceps and soleus) were obtained from the same mouse
strain.
Immunofluorescent staining and confocal microscopy
Isolated mouse ventricular cardiomyocytes in cell suspen-
sion were spun onto poly-Lys-coated slides in a Statspin
cytofuge (600 rpm, 2 min). Cells were fixed in 4 % PFA
and permeabilized in 0.2 % Triton-PBS for 30 min.
Blocking was carried out with 5 % BSA in PBS.
Bundles of skeletal muscle fibres were teased out in
relaxing solution (10 mM EGTA, 5.6 mM MgCl2, 100 mM
KCl, 20 mM imidazole, 5 mM ATP, pH 7.0; supplied with
10 mM creatine phosphate and 500 U/ml creatine kinase)
onto poly-Lys-coated slides. Air-dried slides were rehy-
drated in PBS, then fixed and treated similarly to cardio-
myocytes. Primary antibodies: rabbit anti-c2 (c2C—
C-terminal), 1:60 dilution (gift from D. Carling); rabbit anti-
c2-3B (G2-3B), 1:50 (Pinter et al. 2012a); rabbit anti-c2-
long (G2-L), 1:50 [polyclonal antibody G2-L was raised in
rabbit against the KHL-conjugated peptide 1-20 of c2-long
(MDTKKKKEVSSPGGSSGKKN-C) by Harlan UK (Hill-
crest)]; rabbit AMPKc3 (D-22) (Santa Cruz), 1:50 dilution;
goat AMPKc1 (T-20), 1:50 dilution (Santa Cruz); mouse
anti-myomesin, 1:30 dilution (gift from E. Ehler); mouse
monoclonal anti-a-actinin (EA53), 1:500 dilution (Sigma);
goat L-type Ca2? CP a1D (E-19), 1:50 dilution (Santa Cruz);
goat SERCA2 (N-19), 1:50 dilution (Santa Cruz); mouse
monoclonal anti-slow myosin heavy chain (BA-F8), 1:500
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dilution (DSHB). Primary antibodies were usually applied
overnight at 4 C.
The appropriate fluorescent conjugated secondary anti-
bodies (Alexa Fluor Molecular Probes) were used in 1:400
dilution; both the primary and the secondary antibodies
were diluted in 5 % BSA/PBS. When it was possible,
double staining was carried out. Cells were mounted using
SlowFadeGold antifade reagent with DAPI (Invitrogen),
however the nuclei were actually stained and imaged with
To-Pro3/DNA (Invitrogen) and coloured in blue. Imaging
was performed with a Leica TSC SP5 confocal laser-
scanning microscope with a 639, 1.4NA objective.
Results
Use of AMPKc antibodies to localise AMPK
complexes
AMPK is a trimeric complex and the subunits are not known
to have any role as isolated proteins; therefore by detecting
the c subunits the subcellular localisation of the holoenzyme
can be monitored. Differential localization of the c2 protein
variants is rather challenging. All c2 variants share the entire
sequence of c2-short (Fig. 1) and therefore c2-short cannot
be selectively detected with antibodies. The available c2
antibodies either recognise all three variants (if raised against
sequence within the common nucleotide-binding region) or
one (or both) of the longer forms (if raised against N-terminal
sequences). The epitopes recognised by the three antibodies
used in this study are mapped in Fig. 1. Antibody c2C is a
pan-c2 antibody, with the immunogen being a short peptide
at the C-terminus of all c2 proteins; we have raised G2-L
against the N-terminal peptide of 20 amino acids, and it
exclusively detects c2-long; and G2-3B, that only recognises
c2-3B (Pinter et al. 2012a).
Localisation of AMPKc isoforms in mouse
cardiomyocytes
The G2-3B antibody that selectively reacts with c2-3B,
revealed a principally striated pattern with some nuclear
staining. The striations aligned with the Z-disk as shown by
co-staining with the a-actinin antibody (Fig. 2A). How-
ever, the staining is considerably more punctate and less
uniform than that of a-actinin (higher magnification in the
second row, Fig. 2A), suggesting that AMPK with c2-3B
may associate with structures that align with the Z-disk,
such as the T-tubules and sarcoplasmic reticulum (SR). We
tested this using antibodies against markers of T-tubules
(L-type Ca2? channel) and SR (SR Ca2?-ATPase,
SERCA2); both of these antibodies produced punctate
staining, more similar to c2-3B than to the uniform a-
actinin pattern (Fig. 2B). The terminal cisternae of the SR
form irregular dyads in cardiomyocytes, hence the punctate
staining along the Z-disk. In contrast to the T-tubules of
skeletal muscle, those of the cardiomyocytes can run in a
longitudinal as well as in a transverse direction (Soeller and
Cannell 1999) and the punctate staining pattern with the
T-tubule marker may arise from the longitudinal branches
of the system. Schematic diagram of SR and T-tubular
system in cardiomyocyte is shown in Fig. 2C.
The staining for the minority c2-long variant produced a
mainly Z-disk striated pattern, similar to the c2-3B stain-
ing, along with some staining at the M-line (Fig. 3A). The
C-terminal c2C antibody, which detected three bands in
Western blots of mouse heart tissue (Pinter et al. 2012a)
produced clear staining of both the Z-disk and M-line
regions (Fig. 3A). Whether the M-line signal reflects the
presence of c2-long variant (G2-L antibody detected some
c2-long protein in the M-line), or the c2-short variant is
unclear and is discussed later.
The c1 protein was present in the Z-disk (Fig. 3B). This
is consistent with the earlier report of its localisation in
differentiated mouse myotubes, possibly recruited by
binding plectin, a Z-disk component (Gregor et al. 2006).
No nuclear staining was observed with the c1 antibody in
cardiomyocytes.
Localisation of AMPKc isoforms in mouse skeletal
muscles
The c3 regulatory subunit is mainly expressed in white,
glycolytic fibres of adult skeletal muscle (Mahlapuu et al.
2004). The majority of fibres is type IIB in white quadri-
ceps muscle of mouse (*94 %; fast, glycolytic fibres) and
large proportion of fibres in EDL are also glycolytic
(Bloemberg and Quadrilatero 2012). We isolated and
stained bundles of fibres from EDL and from white quad-
riceps muscles and found c3 staining around the Z-disk
(Fig. 4A), but it is broader than the c1 staining and some
c3 staining is also detectable in the nucleus; nuclear
staining is more obvious in Fig. 4B. The c3 staining
appears as a highly uniform doublet along the Z-disk
(Fig. 4B); the depicted, well-organised structure can be







CBS1 CBS4 CBS3 CBS2 
CBS1 CBS4 CBS3 CBS2 
CBS1 CBS4 CBS3 CBS2 
Fig. 1 Mapping the c2 immunogen sequences on the c2 variants.
Domain diagrams of the three c2 variants showing the unique
sequences of c2-long and c2-3B in grey dotted and solid lines
respectively, along with the location of the immunogen sequences
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The T-tubule marker (L-type Ca2? channel antibody)
and the SERCA2 antibody decorate the T-tubule/SR sys-
tem in skeletal muscle fibres (Fig. 5C). Since the terminal
cisternae of the SR form triads with the T-tubule in skeletal
muscle, the pattern is very regular, rather similar to staining
pattern shown for c3 (Fig. 5B).
We have previously detected c3 expression in the
developing mouse heart; this declines after birth and
appears to be ‘‘replaced’’ by c2-3B expression (Pinter
et al. 2012a). The c subunit ‘‘switch’’ seems to coincide
with metabolic changes: the embryonic heart is mainly
glycolytic while the adult heart is oxidative. We therefore
tested whether the oxidative skeletal muscle fibres con-
tained AMPK c2-3B. When EDL or white quadriceps
fibres were stained with the c2-3B antibody, we detected,
though infrequently, fibres that were stained with c2-3B
antibody; the staining pattern was similar to the c3
staining (Fig. 5A). In contrast, the occurrence of c2-3B-
stained fibres in soleus muscle was higher and imaging is
shown in Fig. 5B. The pattern of c2-3B staining resem-
bles that of c3 (see enlarged segment, Fig. 5B),
suggesting that the two subunits occupy similar positions.
No c2-3B staining was detected in the nuclei (Fig. 5A).
Interestingly, skeletal myopathy has been observed in
patients with PRKAG2 mutations (Murphy et al. 2005);
ragged red fibres with excess mitochondria were detected
but skeletal muscle biopsies of patients presented little
glycogen accumulation.
Although a large proportion of fibres are slow oxidative
type I in mouse soleus muscle (*30 %), about 50 % of the
population are fast oxidative type IIA fibres (Bloemberg
and Quadrilatero 2012). As type I fibres can be identified
by their b myosin heavy chain content, therefore we per-
formed double staining with a slow myosin heavy chain
antibody (MHC-I) and with G2-3B antibody. The mono-
clonal MHC-I antibody recognizes both a and b myosin
heavy chains and decorated cardiomyocytes as expected
(Fig. 6A). Some soleus fibres react with both the MHC-I
and with the c2-3B antibodies but not all c2-3B-reactive
fibres are co-stained with MHC-I (Fig. 6B). The fibres that
are not stained by the slow myosin antibody most likely are
the fast oxidative type II fibres.
2-3B myomesin 2-3B myomesin 













Fig. 2 Subcellular localisation of AMPK c2-3B in mouse ventricular
cardiomyocytes. (A) Localisation of AMPK-c2-3B—G2-3B anti-
body. Enlarged sections (boxed areas) are shown in the second row of
images. (B) Staining pattern of the T-tubules and SR. Z-disk marker is
a-actinin; M-line marker is myomesin. (C) Ultrastructure of cardio-
myocytes—a schematic diagram showing the sarcomere and the
T-tubule/SR system (based on Katz 1975); the terminal cisternae of
SR are highlighted by the red stars



















Fig. 3 Subcellular localisation
of c2 and c1 in mouse
ventricular cardiomyocytes.
(A) Staining patterns produced
by antibodies to c2-long (G2-L)
and by a pan-c2 antibody (c2C).
The strongest staining is around
the Z-disk with these antibodies;
antibodies G2-L and c2C detect
c2 protein in the M-line.
(B) Localisation of AMPK c1 in
the Z-disk by co-staining the
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Fig. 4 Immunofluorescence staining of mouse skeletal muscle fibres.
(A) Localisation of the AMPK c subunits in skeletal muscle fibres.
AMPK with c1 is in the Z-disk; the c3 staining is more punctate
around the Z-disk. There is c3 staining in the nucleus. (B) The
staining pattern for c3 appears to be a very regular doublet flanking
the Z-disk (enlargement of the boxed area, double green arrows).
Nuclear staining with the c3 antibody is very prominent. Marker for
the Z-disk is c1, and myomesin for the M-line. (C) Staining pattern of
the T-tubules/SR system is similar to the c3 staining. (A,C) EDL
muscle fibres; (B) White quadriceps fibres
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Discussion
In mouse cardiomyocytes, the predominant AMPK c2
protein, c2-3B, was shown to give patchy Z-disk staining
and was also found in the nuclei. The punctate Z-disk
staining was similar to the T-tubule and SR markers,
L-type Ca2? channel and SERCA2 respectively. Staining
with a pan-c2 antibody suggested additional M-line local-
isation of either the c2-short or c2-long variants; the latter
was confirmed with a c2-long-specific antibody. Since the
1  2-3B merge 
A 
C 




Fig. 5 Detection of c2-3B in
skeletal muscle fibres. (A) EDL
fibre stained with G2-3B and
a-actinin antibodies. (B) Soleus
fibres; the Z-disk marked by c1
staining. The boxed area is
enlarged and showing the
regular c-3B staining pattern
that is around the Z-disk
(second row of images).
(C) Ultrastructure of skeletal
muscle fibre—a schematic
diagram (based on Eisenberg
et al. 1974); the terminal
cisternae of SR are highlighted
by the red stars
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affinity of the c2C antibody is the same for each c2 protein,
the higher staining intensity in the Z-disk may reflect the
presence of the c2-short, which is the second most abun-
dant c2 protein in cardiomyocytes after c2-3B (Pinter et al.
2012a). The AMPK c2 variants thus appear to localize to
different sarcomeric positions in cardiomyocytes.
Our earlier work has shown that AMPK can phosphor-
ylate cardiac troponin I, both in vitro and in vivo, and that
this phosphorylation modulates the myofilament Ca2?-
sensitivity (Oliveira et al. 2012). This finding was initiated
by the identification of the interaction of cardiac troponin I
with a fragment containing the N-terminal 273 amino acids
of AMPK c2-long by Yeast-Two-Hybrid screening of a
human cardiac cDNA library. However, c2-long and c2-3B
have a common segment in their N-terminal extension, and
since there is much more c2-3B protein than c2-long in
cardiomyocytes (Pinter et al. 2012a), that function may be
linked to AMPK containing c2-3B. Given that there is no
apparent staining throughout the I band, it is possible that
AMPK is recruited to phosphorylate cardiac troponin I and
mobilised from its position around the Z-disk upon
activation.
The c1 protein was localised at the Z-disk in cardio-
myocytes. AMPK with the c1 isoform is known to be
anchored by plectin to the Z-disk in differentiated myo-
cytes (Gregor et al. 2006) and our observation is consistent
with this. The c2-short, similarly to c1, only contains the
nucleotide-binding domain and the highly conserved seg-
ment close to its N-terminus to where the b subunit bind-
ing-site was localised (Viana et al. 2007). We have
reported that c2-short is largely replaced by c1 during
cardiogenesis (Pinter et al. 2012a), suggesting partially or
entirely overlapping function for the two proteins and that
may support the Z-disk localisation of c2-short.
Interestingly, the Z-disk staining with the c1 antibody
resembles the subcellular positions of glycogen synthase
(GS) that is regulated by AMPK (Prats et al. 2005;
Bendayan et al. 2009); glycogen particles are also linked to
the cytoskeleton and so are the glycogen-metabolising
enzymes (Gregor et al. 2006; Graham et al. 2010).
Therefore it is plausible to presume that AMPK with c1 is
involved in the regulation of glycogen metabolism along
with AMPK containing the c2-short subunit.
Both c2-3B and c3, in cardiac and skeletal muscle
respectively, are present along the Z-disk and in the I band;
both staining patterns closely resemble the respective
T-tubule/SR structures. The different appearance of c2-3B
and c3 staining reflects the structural differences of the
T-tubules/SR structures in cardiac and skeletal muscle. In
cardiomyocytes, the T-tubules are aligned with the Z-disk
but a set of two T-tubules, flanking the Z-disk is present in
the I band of skeletal muscle sarcomeres. In cardiac mus-
cle, the arrangement of the terminal cisternae of SR is not
as regular as in skeletal muscle, therefore diads flanking the
Z-disk are formed instead of triads. The structure of the
T-tubule system is also complex, with irregular branching
in heart (Soeller and Cannell 1999).
Given their apparently common T-tubule/SR localisa-
tion, is there any indication that AMPK with c2-3B or c3
have similar functions? A point mutation in c3 causes
glycogen accumulation in skeletal muscle; the cause of this
is not the activation of glycogen synthase or decreased
glycogen utilization but increased glucose uptake (An-
dersson 2003). This mutation is in the first CBS domain, in
the exact position as one of the c2 mutations is; the con-
sequence of the c2 mutation is glycogen deposition in
cardiac tissue (Gollob et al. 2001; Gollob 2003). The










5 µm Fig. 6 Expression of c2-3B and
slow myosin heavy chain in
cardiac and skeletal muscle.
(A) Cardiomyocyte stained with
anti-slow myosin heavy chain
(MHC-I); (B) A selection of
soleus muscle fibres stained
with both G2-3B and MHC-I
antibodies. The weak M-line
staining with G2-3B may depict
the M-line part of the SR (see
diagram in Fig. 5C)
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oxidative during differentiation; in parallel, there is an
apparent switch from c3 to c2-3B expression in the
developing heart (Pinter et al. 2012a). Glucose transport is
mainly mediated by GLUT1 and GLUT4 in cardiomyo-
cytes (Stanley et al. 1997) and myocardial AMPK activa-
tion and subsequent GLUT-4 translocation to the
sarcolemma was reported in rat (Russell et al. 1999). The
sodium/glucose cotransporter (SGLT1) is also expressed in
heart (Banerjee et al. 2009) and AMPK activation was also
reported to trigger the increased membrane translocation of
SGLT1 (Sopjani et al. 2010).
In skeletal muscle, a2/b2/c3 complexes become pref-
erentially activated during exercise (Birk and Wojtaszew-
ski 2006); a2-AMPK was identified as an endoplasmic
reticulum (ER) stress suppressor as its activation maintains
SERCA activity and intracellular Ca2? homeostasis (Dong
et al. 2010). The expression c3 is restricted to glycolytic
fast fibres; oxidative fibres (slow or fast) seem to contain
c2-3B. Mitochondria are tethered to the SR in both skeletal
muscle fibres and in cardiomyocytes (Boncompagni et al.
2009) where we detected c2-3B. It has been reported that
AMPK phosphorylates PGC1a and instead of affecting the
mitochondrial oxidative capacity it stimulate mitochondrial
biogenesis (Jager et al. 2007). A PRKAG2 mutation was
shown to cause myopathy in red muscle (Murphy et al.
2005) and ragged red fibres were observed with mito-
chondria accumulation but without substantial glycogen
deposition. This observation also supports our finding that
c2-3B is only expressed in oxidative muscle (cardiomyo-
cytes, slow type I and fast type II skeletal muscle fibres),
however we have not done the thorough fibre type
matching.
Furthermore, several ion channels are regulated by
AMPK, some of them by direct phosphorylation (reviewed
by Andersen and Rasmussen 2012). In a recent study
AMPK phosphorylation of the voltage-gated Kv2.1K-
channel was demonstrated in neurons, where AMPK acti-
vation reduced excitability to conserve energy (Ikematsu
et al. 2011). Kv2.1 is present in all part of the transverse
and axial tubule system in cardiomyocytes (O’Connell
et al. 2008). Ion channel down-regulation by AMPK has
been reported; one of them is the KCNQ1 potassium
channel. KCNQ1 ubiqutination is promoted by AMPK
activation via the ubiqutin-protein ligase, Nedd4-2 in kid-
ney cells (Alzamora et al. 2010). KCNQ1 is expressed in
cardiomyocytes, where its abnormal trafficking was linked
to hereditary long QT syndrome (Wilson et al. 2005).
AMPK associated with the T-tubules may regulate ion
transport, contributing perhaps to conductive irregularities
that accompany cardiac hypertrophy caused by PRKAG2
mutations.
In summary, we have demonstrated AMPK compart-
mentalisation in cardiomyocytes and in skeletal muscle
fibres and showed that differential localisation of the dif-
ferent AMPK complexes is most likely governed by the
regulatory subunits, either by the different c isoforms or by
the variants of c2. By compartmentalisation, the different
AMPK complexes are most probably assigned different
functions. Mutation in the c2 proteins would alter these
functions; as a consequence, this could trigger mechanisms
to cause the different aspects of the cardiac disease
(hypertrophy, conductive disorder, glycogen deposition).
However, further studies needed to understand the impor-
tance and the dynamics of the compartmentalisation of the
c2-AMPK complexes, focusing on specific interactions in
each location. The need for isoform-selective activation of
AMPK to develop cardioprotective therapies has been
highlighted in a recent review article (Kim and Tian 2011)
and protein–protein interaction studies could result in new
drug designs that acts specifically on c2-AMPK complexes
to ameliorate the disease caused by the PRKAG2
mutations.
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